About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

psoriatric arthritis Guideline Released

by Colleen Fleiss on December 5, 2018 at 3:12 AM
Font : A-A+

psoriatric arthritis Guideline Released

A joint treatment guideline for psoriatric arthritis (PsA) has been released by The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF). The new guideline provides evidence-based pharmacologic and non-pharmacologic recommendations on caring for treatment-naïve patients with active PsA and patients who continue to have active PsA despite treatment.

PsA is a chronic inflammatory musculoskeletal disease most commonly found in patients with psoriasis, a skin disease that causes red, scaly patches to appear on the skin. According to the NPF, more than 8 million Americans suffer from psoriasis, and it is estimated that 30 percent of them may develop PsA.

Advertisement


Some key recommendations from the guideline include:

A conditional recommendation to use treat-to-target approach for all patients with active PsA;

A conditional recommendation to use tumor necrosis factor inhibitor (TNFi) biologics as a first-line therapy option in patients with active PsA; and
Advertisement

A strong recommendation for smoking avoidance/cessation

"Treat-to-target is key, because it encompasses all clinical scenarios, rather than one particular clinical situation," said Jasvinder Singh, MD, MPH, a rheumatologist at the University of Alabama at Birmingham who served as principal investigator for the guideline project. "The available evidence suggests the irreversible joint damage, associated functional limitations, joint deformities and disability associated with PsA could possibly be avoided/delayed with optimal disease management using a targeted approach. A targeted approach can also improve pain, function and quality of life and social participation."

The use of TNFi biologics as a first-line therapy was one of many recommendations included to help providers and patients decide between the various pharmacologic options currently available. While current GRAPPA recommendations address the use of TNFi biologics in treatment-naïve patients, this is the first guideline that specifically recommends first trying them over oral small molecule (OSM) drugs.

"The available evidence suggested that in the absence of certain conditions, many treatment-naïve patients would benefit from trying a TNFi biologic first," said Dafna Gladman, MD, a rheumatology professor of medicine at the University of Toronto and member of the NPF Medical Board who served as a content expert on the guideline's core team. "This doesn't hold true once other symptoms and comorbidities are present, so OSMs can continue to be a first-line option for patients that have contraindications to TNFi treatment, as well as patients without severe PsA or psoriasis that prefer oral therapy. Providers should take into consideration all active disease domains, comorbidities, and the patient's functional status when choosing the optimal therapy for an individual at a given point in time."

Tofacitinib was not included within the OSM category since its benefit/risk profile differs from that of the rest of the OSMs.

The strong recommendation for smoking cessation was based on evidence linking smoking to a reduced efficacy of biologics; the benefits of smoking cessation; and the well-established link of smoking with mortality, cancers and heart and lung diseases in the general population.

The PsA guideline was developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, which provides rigorous standards for judging the quality of the literature available and assigns strengths to the recommendations that are largely based on the quality of the available evidence. Due to limited data in some areas, the quality of evidence was often graded low or very low. This led to nearly all recommendations being conditional. A voting panel of rheumatologists, dermatologists, health professionals, and patients achieved consensus on the direction and the strength of the recommendations.

"Despite an expansion in the number of new therapies for the treatment of PsA, only limited studies comparing effectiveness exist to inform treatment decisions," said Singh. "This indicates a need for head-to-head trials of various treatments and comparative effectiveness studies in both trial populations and PsA populations with comorbidities. We also need studies in patients with active PsA who are treatment-naïve, or who have tried and failed different treatment approaches. The presence of high-quality evidence will allow formulation of strong treatment recommendations."

The complete guideline is available online on both the ACR website and NPF website.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Insulin Resistance Doubles the Risk of Major Depressive Disorder
Emotional Healing
Psychosis Risk Related to Cat Parasite
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Osteoarthritis Oligoarthritis Spondylolisthesis Knee Replacement Reactive Arthritis Arthritis Septic Arthritis Physiotherapy for Arthritis Adult-Onset Stillīs Disease COX - 2 Inhibitors 

Recommended Reading
Psoriatic Arthritis
Psoriatic arthritis is a kind of autoimmune inflammatory arthritis, which develops in 30 percent of ...
Current Psoriatic Arthritis (PsA) Treatment may be Inefficient
The health-related quality of life impairment among Psoriatic Arthritis (PsA) patients increased as ...
Varied Symptoms of Psoriatic Arthritis Makes Diagnosis Difficult
Psoriatic arthritis is often undiagnosed or misdiagnosed. There is no definitive test for it and so ...
Co-morbidity Tool To Predict Risk in Psoriatic Arthritis
Psoriatic Arthritis is an inflammatory arthritis associated with joint pain and swelling which can ....
Adult-Onset Stillīs Disease
Adult-Onset Still’s Disease is a rare, inflammatory form of arthritis characterized by fever, pink r...
COX - 2 Inhibitors
What are COX–2 Inhibitors? Why are they safer compared to NSAIDs and which conditions are best trea...
Knee Replacement
Make sprinting a possibility! Relieve chronic arthritic pain by having a knee replacement done at ...
Oligoarthritis
Most parents when told that their child has arthritis find it hard to believe it, as arthritis is re...
Osteoarthritis
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of a...
Physiotherapy for Arthritis
Physiotherapy enables patients with debilitating disease to regain loss of function in their muscles...
Reactive Arthritis
Reactive arthritis is an autoimmune condition. Ankylosing spondylitis, psoriatic arthritis are disor...
Septic Arthritis
Septic Arthritis or Infectious Arthritis is infection of a joint due to bacteria or other organisms....
Spondylolisthesis
Spondylolisthesis is a condition of the lower spine in which one of the bones of the vertebral colum...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use